Zelira Therapeutics Ltd. · ASX:ZLD
Zelira Therapeutics — Non-Deal Roadshow (May 2022)
28 slides from Zelira Therapeutics's roadshow presentation, May 12, 2022
Slide 1: Zelira Therapeutics
For personal use only ZELIRA THERAPEUTICS A Global Biopharmaceutical Company Developing and Marketing Clinically Validated Cannabinoid-Based Medicines ASX: ZLD OTCQB:ZLDAF zeliratx.com
Slide 2: Disclaimer & Important Notice
Disclaimer & Important Notice For personal use only Disclaimer Future Matters This presentation has been prepared by Zelira Therapeutics Ltd ACN 103 782 378 (“Company”). It doesnot purport to This presentation contains reference to certain intentions, contain all the information that a prospective i
Slide 3: Company Overview
COMPANY OVERVIEW For personal use only Zelira is a global biopharmaceutical company developing and marketing clinically validated cannabinoid-based medicines. It offers investors exposure to a rapidly emerging global industry at a very attractive valuation, with multiple shots on goal - to create si
Slide 4: Overview of Zelira Therapeutics
Overview of Zelira Therapeutics For personal use only Global Markets Strategy Clinical Validation Focus Global Product Launch Rx & OTC Development and Commercialization strategies US, Australia, UK and EU footprint Leading pipeline of products in clinical Portfolio of branded, validated to rapidly a
Slide 5: Milestones achieved in 2020
2020 Milestones achieved in 2020 For personal use only 14 July 2020 9 Nov 2020 16 Sept 2020 Zelira® reports Phase 1 dose Zelira® partners with Emyria for Zenivol® launched in Australia escalation study in chronic pain Autism Observational Trial for as the world’s most clinically patients on long-ter
Slide 6: Milestones achieved in 2021
2021 Milestones achieved in 2021 For personal use only 3 June 2021 21 June 2021 20 October 2021 Levin health licensing and Clinical trial results of Zelira’s Zelira® raises US$5 million from management agreement signed to Zenivol® published in prestigious Quincy Street Capital LLC, a conduct chronic
Slide 7: Significant Events
SIGNIFICANT EVENTS At a Group level, fundraising values Zelira® at A$122.8M For personal use only September 2020, Zelira® completed a Australian operations remain Milestones of US based product placement of A$2 million to the Thorney a core and important part of sales exceeded US $1 million Investme
Slide 8: Revenue Streams
REVENUE STREAMS For personal use only Revenue Stream 2 Oral Health Revenue Stream 4 OTC Clinical Trials Toothpaste Rx Additional Products, 2022 Launch Insomnia Opioid Sparing Autism Revenue Stream 3 Dermatology OTC Revenue Stream 1 Revenue Stream 5 Five acne treating Launch & Learn products launched
Slide 9: Rapid Commercialisation Strategy
RAPID COMMERCIALISATION STRATEGY For personal use only Launch Learn Develop Generate proprietary formulations Collect real-world patient data Patient data informs and de-risks design of clinical trial Launch products in global markets Refine product to meet patient needs 43% costs reimbursable via R
Slide 10: Pipeline
PIPELINE Product Status Current Markets Next Steps For personal use only Launched Autism | HOPE® 2020 USA AUS GERMANY UK NZ Launched Insomnia | Zenivol® 2020 AUS USA GERMANY UK NZ Launched Oral Care | SprinJene CBD 2021 USA UK ADDITIONAL PRODUCTS Launched Dermatology | RAF FIVE™ 2021 USA IRB approve
Slide 11: HOPE for Behaviours associated with Autism Spectrum Disorder
Overview HOPE® for Behaviours For personal use only • HOPE® developed with and for the Autism community associated with Autism • Published Real life data report-HOPE® improves autism-related behaviours and quality of Spectrum Disorder life for survey participants Rx US Revenues: Licensed in Louisian
Slide 12: Zenivol for chronic, unresolved insomnia
Overview Zenivol® for chronic, For personal use only • World’s first clinically validated cannabinoid drug for chronic insomnia unresolved insomnia • Phase 1B/2A clinical trial confirmed Zenivol® safe, efficacious and improved quality of life Rx • Significant reduction in insomnia symptoms • Clinica
Slide 13: Oral Care – SprinJene CBD
Overview Oral Care – Sprinjene CBD For personal use only • Full line of CBD oral care products OTC Toothpaste was launched in Q1 2021 and generating revenue with strong growth potential Available for purchase on zeliraoralcare.com, sprinjenecbd.com, amazon.com and wholesale distribution channels in
Slide 14: Oral Care – SprinJene CBD
Relieve dry Relieve mouth dry Relieve dryRelieve mouth mouthdry mouth Reduce gum Reduce inflammation Reduce gum Reduce gum inflammation gum inflammation inflammation Freshen breath Freshen Freshen breath Freshen breath breath Remove surface Remove Removestains surface Remove surface stains surface s
Slide 15: Oral Care – SprinJene CBD Ingredients
Oral Care – Sprinjene CBD For personal use only Ingredients featured in CBD SprinJene Natural Toothpaste help... Protect teeth from decay Fight gingivitis Control bacteria, plaque, and tartar Relieve dry mouth Reduce gum inflammation Freshen breath Remove surface stains Bursting with the unique Blac
Slide 16: Differentiated Dermatology
Overview Differentiated dermatology For personal use only • Science-backed Platform Technology • Innovative Branding and OTC • Focus on significant unmet needs in Market–ready products Dermatology • World Class Inventors and Formulators Dr. Karyn Grossman in the News ZylormaTM, a proprietary, patent
Slide 17: RAF FIVE Product Range
RAF FIVE™ Product Range For personal use only CONFIDENTIAL UNDER TERMS OF NON-DISCLOSURE AGREEMENT
Slide 18: For personal use only
WASH AWAY GEL CLEANSER AFTER HOURS MOISTURIZING For personal use only ACNE TREATMENT LOTION ACNE TREATMENT CLEAR THE WAY WASH UP ACNE CLEANSER ACNE TREATMENT PADS KICK OFF HYDRATING LOTION BROAD SPECTRUM SPF 30 SUNSCREEN CONFIDENTIAL UNDER TERMS OF NON-DISCLOSURE AGREEMENT
Slide 19: Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology
Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology For personal use only Zelira has successfully developed and demonstrated enhanced dissolution of cannabinoids using its enhanced distillate capture and dissolution matrix (EDCDM) • Breakthrough technology developed by Zelira. • ED
Slide 20: Enhanced Distillate Capture and Dissolution Matrix (EDCDM)
Enhanced Distillate Capture and Dissolution Matrix (EDCDM) For personal use only DIFFICULTY WITH FORMULATION AND DEVELOPMENTS OF FREE FLOW CANNABINOID CAPSULES AND TABLETS DUE TO NON DISTILLATE UNIFORMITY AND SEPARATING FROM POWDER BED This novel matrix absorbs the distillate into a nano EDCDM porou
Slide 21: Zelira Patent Portfolio
Zelira Patent Portfolio For personal use only Zelira’s patent portfolio has been granted or under consideration in 26 countries spanning across the globe. There are 41 patents granted and 103 under prosecution across 9 different therapeutic areas Therapeutic Area Granted/Allowed Under Prosecution/Ex
Slide 22: Financial Media Coverage
Financial Media Coverage For personal use only 1 Zenivol® clinical trial results published in the prestigious peer-reviewed journal SLEEP® 2 Clinical Pain Trial with Retired Professional Athletes 3 Breakthrough Research Demonstrates Significant Uptake of CBD Into the Brain Zelira® to launch CBD toot
Slide 23: Financial Media Coverage (continued)
For personal use only 7 Moved Global Headquarters to Pennsylvania to Optimize U.S. Cannabis Market Exposure 8 Zelira® enters Germany, Europe’s largest medicinal cannabis market, via an exclusive distribution agreement with Adjupharm GmbH 9 Zelira® Launches RAF FIVE™ Acne Treatment products through i
Slide 24: Health House International Ltd Acquisition
Zelira Therapeutics Founder & Chairman Osagie Imasogie said: Health House International Ltd “The proposed acquisition of Health House will provide Zelira with control of For personal use only Acquisition direct access to highly regulated European and other markets for it’s products. In addition, the
Slide 25: Health House International Ltd Acquisition: Combined Value Proposition
Health House International Ltd Acquisition For personal use only Combined Value Proposition Accelerated revenues Direct access to GMP Access to European, Control of direct access and accelerates the manufacturing facilities US and Australian to highly regulated product pipeline in Europe opportuniti
Slide 26: Corporate Snapshot
Corporate Snapshot For personal use only Financials (as at 29 April 2022) Share Price (Market Data as at 29 April 2022) AUD$ Share Price 2.10 52w Range 2.10 - 9.97 Market Capitalisation 20M Cash (at 31 March 2022) 4.6M Capital Structure (Fully Diluted2) Structure Major Shareholders Directors Holding
Slide 27: Global Board of Directors
Global Board of Directors For personal use only GLOBAL Dr. Oludare Odumosu CEO & Managing Director • Post-clinical development of Iroko Pharmaceutical’s Zorvolex® Tivorbex® and Vivlodex® through FDA approvals and successful US market commercialization. • Founding COO of Ilera Healthcare. Ilera Healt
Slide 28: Thank You
For personal use only Thank You Zelira Therapeutics Phone +1-484-630-0650 | Email info@zeliratx.com zeliratx.com